|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
143 a.a.
|
 |
|
|
|
|
|
|
|
219 a.a.
|
 |
|
|
|
|
|
|
|
215 a.a.
|
 |
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Cytokine/immune system
|
 |
|
Title:
|
 |
Structure of cd40l in complex with the fab fragment of humanized 5c8 antibody
|
|
Structure:
|
 |
Cd40 ligand. Chain: a, b, c. Fragment: residues 116-261. Synonym: cd40-l. Engineered: yes. Immunoglobulin h. Chain: h, k, x. Immunoglobulin l. Chain: l, m, y
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: pichia pastoris. Expression_system_taxid: 4922. Cell_line: nso myeloma. Cell_line: nso myeloma
|
|
Biol. unit:
|
 |
Nonamer (from
)
|
|
Resolution:
|
 |
|
3.10Å
|
R-factor:
|
0.233
|
R-free:
|
0.285
|
|
|
Authors:
|
 |
M.Karpusas,J.Lucci,J.Ferrant,C.Benjamin,Y.-M.Hsu
|
Key ref:
|
 |
M.Karpusas
et al.
(2001).
Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody.
Structure,
9,
321-329.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
20-Mar-01
|
Release date:
|
20-Mar-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P29965
(CD40L_HUMAN) -
CD40 ligand
|
|
|
|
Seq: Struc:
|
 |
 |
 |
261 a.a.
143 a.a.
|
|
|
|
|
|
|
 |
 |
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
membrane
|
1 term
|
 |
|
Biological process
|
immune response
|
1 term
|
 |
|
Biochemical function
|
tumor necrosis factor receptor binding
|
1 term
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Structure
9:321-329
(2001)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure of CD40 ligand in complex with the Fab fragment of a neutralizing humanized antibody.
|
|
M.Karpusas,
J.Lucci,
J.Ferrant,
C.Benjamin,
F.R.Taylor,
K.Strauch,
E.Garber,
Y.M.Hsu.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: CD40 ligand (CD40L or CD154), a member of the tumor necrosis factor
(TNF) family, plays a critical role in both humoral and cellular immune
responses and has been implicated in biological pathways involving epithelial
cells, fibroblasts, and platelets. Such a pathway is T cell-mediated B cell
activation, a process that occurs through the interaction of CD40L with CD40
receptor expressed on B cells. It results in various B cell responses, including
immunoglobulin isotype switching and B cell differentiation and proliferation.
These responses can be inhibited by the monoclonal antibody 5c8, which binds
with high affinity to CD40L. RESULTS: To understand the structural basis of the
inhibition, we determined the crystal structure of the complex of the
extracellular domain of CD40L and the Fab fragment of humanized 5c8 antibody.
The structure shows that the complex has the shape of a three-bladed propeller
with three Fab fragments bound symmetrically to a CD40L homotrimer. To further
study the nature of the antibody-antigen interface, we assessed the ability of
23 site-directed mutants of CD40L to bind to 5c8 and CD40 and analyzed the
results in the context of the crystal structure. Finally, we observed via
confocal microscopy that 5c8 binding to CD40L on the cell surface results in the
formation of patches of clustered complexes. CONCLUSIONS: The structure reveals
that 5c8 neutralizes CD40L function by sterically blocking CD40 binding. The
antigenic epitope is localized in a region of the surface that is likely to be
structurally perturbed as a result of genetic mutations that cause hyper-IgM
syndrome. The symmetric trimeric arrangement of the Fab fragments in the complex
results in a geometry that facilitates the formation of large clusters of
complexes on the cell surface.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
Figure 2.
Figure 2. The Crystal Structure of the CD40L-5c8 Fab
Complex in Ribbon RepresentationThe top view is along the
three-fold axis, while the bottom view is perpendicular to the
three-fold axis. The three CD40L monomers are colored yellow,
green, and dark blue. The three Fab heavy chains are colored
gray, dark gray, and magenta. The figure was made with RIBBONS
[39] 
|
 |
|
|
|
| |
The above figure is
reprinted
by permission from Cell Press:
Structure
(2001,
9,
321-329)
copyright 2001.
|
|
| |
Figure was
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
I.N.Ugwumba,
K.Ozawa,
L.de la Cruz,
Z.Q.Xu,
A.J.Herlt,
K.S.Hadler,
C.Coppin,
S.E.Brown,
G.Schenk,
J.G.Oakeshott,
and
G.Otting
(2011).
Using a genetically encoded fluorescent amino acid as a site-specific probe to detect binding of low-molecular-weight compounds.
|
| |
Assay Drug Dev Technol, 9,
50-57.
|
 |
|
|
|
|
 |
E.Margolles-Clark,
N.S.Kenyon,
C.Ricordi,
and
P.Buchwald
(2010).
Effective and specific inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative.
|
| |
Chem Biol Drug Des, 76,
305-313.
|
 |
|
|
|
|
 |
S.J.Black,
P.Guirnalda,
D.Frenkel,
C.Haynes,
and
V.Bockstal
(2010).
Induction and regulation of Trypanosoma brucei VSG-specific antibody responses.
|
| |
Parasitology, 137,
2041-2049.
|
 |
|
|
|
|
 |
Z.S.Derewenda
(2010).
Application of protein engineering to enhance crystallizability and improve crystal properties.
|
| |
Acta Crystallogr D Biol Crystallogr, 66,
604-615.
|
 |
|
|
|
|
 |
B.Yan,
S.Steen,
D.Hambly,
J.Valliere-Douglass,
T.Vanden Bos,
S.Smallwood,
Z.Yates,
T.Arroll,
Y.Han,
H.Gadgil,
R.F.Latypov,
A.Wallace,
A.Lim,
G.R.Kleemann,
W.Wang,
and
A.Balland
(2009).
Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain.
|
| |
J Pharm Sci, 98,
3509-3521.
|
 |
|
|
|
|
 |
C.J.Qi,
L.Zheng,
H.B.Ma,
M.Fei,
K.Q.Qian,
B.R.Shen,
C.P.Wu,
M.Vihinen,
and
X.G.Zhang
(2009).
A novel mutation in CD40 and its functional characterization.
|
| |
Hum Mutat, 30,
985-994.
|
 |
|
|
|
|
 |
J.H.Mills,
H.S.Lee,
C.C.Liu,
J.Wang,
and
P.G.Schultz
(2009).
A genetically encoded direct sensor of antibody-antigen interactions.
|
| |
Chembiochem, 10,
2162-2164.
|
 |
|
|
|
|
 |
M.Orzáez,
A.Gortat,
L.Mondragón,
and
E.Pérez-Payá
(2009).
Peptides and peptide mimics as modulators of apoptotic pathways.
|
| |
ChemMedChem, 4,
146-160.
|
 |
|
|
|
|
 |
L.A.Clark,
and
H.W.van Vlijmen
(2008).
A knowledge-based forcefield for protein-protein interface design.
|
| |
Proteins, 70,
1540-1550.
|
 |
|
|
|
|
 |
L.Zheng,
I.O.Carbone,
A.Lugovskoy,
B.A.Berg,
and
W.Yang
(2008).
A hybrid recursion method to robustly ensure convergence efficiencies in the simulated scaling based free energy simulations.
|
| |
J Chem Phys, 129,
034105.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
| |